文献速递老年与多病共存慢病管理基层心理健康

临床医生视角下痴呆共病患者优化处方的障碍与促进因素

Clinicians' Perspectives on Barriers and Enablers of Optimal Prescribing in Patients with Dementia and Coexisting Conditions.
PubMed 文献 · J Am Board Fam Med · 2019-01-01

本研究通过半结构化访谈12名基层和9名专科临床医生,探讨痴呆共病患者优化处方的障碍与促进因素。医生认为口服抗凝药、降糖药、他汀类、膀胱抗胆碱能药和抗精神病药决策最具挑战。障碍包括缺乏痴呆患者用药疗效安全性数据、难以评估个体药物效应及停药被视为「放弃」,促进因素包括跨学科服务可及性和针对共病的痴呆照护指南。

要点

  • 痴呆共病患者优化处方面临多重障碍,尤其是缺乏该人群用药疗效安全性数据。
  • 口服抗凝药、降糖药、他汀类、膀胱抗胆碱能药和抗精神病药决策最具挑战。
  • 跨学科服务可及性和针对共病的痴呆照护指南是优化处方的促进因素。

核心结论

  • 临床医生识别出痴呆共病患者优化处方的诸多障碍和部分促进因素。
  • 需要更多关于该人群停药获益与危害的数据。
  • 研究应测试支持痴呆患者和照护者知情决策的不同方法。

研究设计与样本

  • 定性研究,对城市、郊区、农村的基层和专科临床医生进行半结构化访谈。
  • 访谈12名基层和9名专科临床医生,平均(SD)年龄47(9)岁,平均(SD)执业14(10)年。
  • 采用定性内容分析对转录文本进行分析。

主要发现

  • 医生认为口服抗凝药、降糖药、他汀类、膀胱抗胆碱能药和抗精神病药的决策尤其具有挑战性。
  • 优化处方的促进因素包括跨学科服务可及性和针对非痴呆疾病(如糖尿病)的指南涵盖痴呆患者照护。
  • 障碍包括缺乏大多数药物在痴呆患者中的疗效和安全性数据、难以评估个体患者药物效应、以及停药被视为「放弃」的看法。
  • 临床医生采用多种策略与患者和照护者讨论药物风险与获益。

临床怎么用

  • 临床医生应关注痴呆共病患者中口服抗凝药、降糖药、他汀类、膀胱抗胆碱能药和抗精神病药的处方优化。
  • 可利用跨学科服务和针对共病的痴呆照护指南促进优化处方。
  • 与患者和照护者讨论药物风险与获益时可采用多种策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with dementia experience high rates of polypharmacy, potentially inappropriate medication use, and adverse drug events. There is little guidance for clinicians on how to optimize prescribing for this population. Our objective was to investigate clinician-perceived barriers to and facilitators of optimizing prescribing for people with dementia. METHODS: Qualitative study involving semistructured interviews of primary care and specialist clinicians in urban, suburban, and rural settings. Transcripts were analyzed using qualitative content analysis. RESULTS: Interviews were conducted with 12 primary care and 9 specialist clinicians, with a mean (SD) age of 47 (9) and mean (SD) of 14 (10) years in practice. Clinicians cited decisions regarding the following drug classes as particularly challenging: oral anticoagulants, antidiabetic agents, statins, bladder antimuscarinics, and antipsychotics. Perceived enablers of optimizing prescribing included access to interdisciplinary services and guidelines for nondementia illnesses (eg, diabetes) addressing the care of people with dementia. Barriers included the lack of data on efficacy and safety of most medications in people with dementia, difficulty assessing medication effects in an individual patient, and the perception that stopping medications is seen as "giving up." Clinicians used a variety of strategies to discuss risks and benefits of medications with patients and caregivers. CONCLUSIONS: Clinicians identified numerous barriers to and some facilitators of optimizing prescribing in people with dementia. More data are needed on the benefits and harms of stopping medications in this population. Research should also test different approaches for supporting informed decision making about medications by people with dementia and caregivers.

来源:J Am Board Fam Med,查看原文。版权归原作者所有。

引用

  1. Green AR, Lee P, Reeve E, et al. Clinicians' Perspectives on Barriers and Enablers of Optimal Prescribing in Patients with Dementia and Coexisting Conditions. J Am Board Fam Med. 2019. PMID: 31068402. doi:10.3122/jabfm.2019.03.180335

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。